Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 15/20 | 0.51 |
| ▸ | PIK3CG | P48736 | 12/20 | 0.51 |
| ▸ | PIK3CA | P42336 | 11/20 | 0.51 |
| ▸ | PIK3CB | P42338 | 10/20 | 0.51 |
| ▸ | AKT1 | P31749 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
| ▸ | PI4KA | P42356 | 1/20 | 0.38 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.38 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1118950 | 0.91 | PIK3CD (0.52) | PIK3CDPIK3CGPIK3CAPIK3CBPI4KA | |
| SCHEMBL2216932 | 0.88 | PIK3CD (0.41) | PIK3CDPIK3CGPIK3CAPIK3CB | |
| SCHEMBL1772959 | 0.87 | PIK3CG (0.44) | PIK3CDPIK3CGPIK3CAPIK3CBAKT1 | |
| SCHEMBL2056477 | 0.85 | PIK3CD (0.52) | PIK3CDPIK3CGPIK3CAPIK3CBPI4KA | |
| SCHEMBL463255 | 0.79 | PIK3C3 (0.38) | PIK3CDPIK3CGPIK3CAPIK3CBEGFR | |
| SCHEMBL1772776 | 0.78 | PIK3CD (0.49) | PIK3CDPIK3CGPIK3CAPIK3CBPI4KA | |
| SCHEMBL2212140 | 0.78 | PIK3CD (0.46) | PIK3CDPIK3CGPIK3CAPIK3CB | |
| SCHEMBL1118851 | 0.78 | PIK3CG (0.52) | PIK3CDPIK3CGPIK3CAPIK3CBEGFR | |
| SCHEMBL2215940 | 0.77 | PIK3CD (0.39) | PIK3CDPIK3CGPIK3CAPIK3CB | |
| SCHEMBL2210199 | 0.77 | PIK3CD (0.38) | PIK3CDPIK3CGPIK3CAPIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2280946-B1 | 4-CARBOXAMIDE INDAZOLE DERIVATIVES USEFUL AS INHIBITORS OF P13-KINASES | GLAXO GROUP LTD (GB) | 2016-02-10 | — | — | EP | disclosed |
| EP-2280946-B1 | 4-CARBOXAMIDE INDAZOLE DERIVATIVES USEFUL AS INHIBITORS OF P13-KINASES | GLAXO GROUP LTD (GB) | 2016-02-10 | — | — | EP | disclosed |
| US-8163743-B2 | 4-carboxamide indazole derivatives useful as inhibitors of PI3-kinases | GlaxoGroupLimited (GB) | 2012-04-24 | — | — | US | disclosed |
| US-8163743-B2 | 4-carboxamide indazole derivatives useful as inhibitors of PI3-kinases | GlaxoGroupLimited (GB) | 2012-04-24 | — | — | US | disclosed |
| US-8163743-B2 | 4-carboxamide indazole derivatives useful as inhibitors of PI3-kinases | GlaxoGroupLimited (GB) | 2012-04-24 | — | — | US | disclosed |
| US-20110112070-A1 | 4-CARBOXAMIDE INDAZOLE DERIVATIVES USEFUL AS INHIBITORS OF P13-KINASES | GLAXO GROUP LIMITED (GB) | 2011-05-12 | — | — | US | disclosed |
| US-20110112070-A1 | 4-CARBOXAMIDE INDAZOLE DERIVATIVES USEFUL AS INHIBITORS OF P13-KINASES | GLAXO GROUP LIMITED (GB) | 2011-05-12 | — | — | US | disclosed |
| US-20110112070-A1 | 4-CARBOXAMIDE INDAZOLE DERIVATIVES USEFUL AS INHIBITORS OF P13-KINASES | GLAXO GROUP LIMITED (GB) | 2011-05-12 | — | — | US | disclosed |
| WO-2009147187-A1 | 4-CARBOXAMIDE INDAZOLE DERIVATIVES USEFUL AS INHIBITORS OF P13-KINASES | GLAXO GROUP LIMITED (GB) | 2009-12-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112070-A1 | 4-CARBOXAMIDE INDAZOLE DERIVATIVES USEFUL AS INHIBITORS OF P13-KINASES | CDK3, CDK13, MAP3K13 | PIK3CD 111/4885PIK3CG 181/4885PIK3CA 64/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.